TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference77 articles.
1. A comparison of Regorafenib and TAS-102 for metastatic colorectal Cancer: A systematic review and network meta-analysis;Abrahao;Clinical Colorectal Cancer,2018
2. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer;Andersen;Acta Oncologica,2019
3. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer;Argilés;European Journal of Cancer,2019
4. Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine;Baba;Molecular Oncology,2017
5. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201);Bando;European Journal of Cancer,2016
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A one-dimensional bacterial cellulose nano-whiskers-based binary-drug delivery system for the cancer treatment;International Journal of Biological Macromolecules;2024-11
2. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience;Gastric Cancer;2023-09-04
3. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma;The Oncologist;2023-06-20
4. Effects and mechanisms of trifluridine alone or in combination with cryptotanshinone in inhibiting malignant biological behavior of gastric cancer;Cell Cycle;2023-06-04
5. Research progress of traditional Chinese medicine as sensitizer in reversing chemoresistance of colorectal cancer;Frontiers in Oncology;2023-03-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3